Ethical and legal issues in psychedelic harm reduction and integration therapy
Psychedelic-assisted therapy may represent an upcoming paradigm shift in the treatment of mental health problems as recent clinical trials have demonstrated strong evidence of their therapeutic benefits. While psychedelics are currently prohibited substances in most countries, the growing popularity...
Saved in:
Published in | Harm reduction journal Vol. 18; no. 1; pp. 40 - 14 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
England
BioMed Central Ltd
07.04.2021
BioMed Central BMC |
Subjects | |
Online Access | Get full text |
ISSN | 1477-7517 1477-7517 |
DOI | 10.1186/s12954-021-00489-1 |
Cover
Loading…
Abstract | Psychedelic-assisted therapy may represent an upcoming paradigm shift in the treatment of mental health problems as recent clinical trials have demonstrated strong evidence of their therapeutic benefits. While psychedelics are currently prohibited substances in most countries, the growing popularity of their therapeutic potential is leading many people to use psychedelics on their own rather than waiting for legal medical access. Therapists therefore have an ethical duty to meet this need by providing support for clients using psychedelics. However, incorporating psychedelics into traditional psychotherapy poses some risk given their prohibited status and many therapists are unsure of how they might practice in this area. This paper explicates such risks and describes ways in which therapists can mitigate them and strive to practice within legal and ethical boundaries. A harm reduction approach will be emphasized as a useful framework for conducting therapy around clients' use of psychedelics. It is argued that therapists can meet with clients before and after their own personal psychedelic experiences in order to help clients minimize risk and maximize benefit. Common clinical scenarios in this growing clinical area will also be discussed. |
---|---|
AbstractList | Psychedelic-assisted therapy may represent an upcoming paradigm shift in the treatment of mental health problems as recent clinical trials have demonstrated strong evidence of their therapeutic benefits. While psychedelics are currently prohibited substances in most countries, the growing popularity of their therapeutic potential is leading many people to use psychedelics on their own rather than waiting for legal medical access. Therapists therefore have an ethical duty to meet this need by providing support for clients using psychedelics. However, incorporating psychedelics into traditional psychotherapy poses some risk given their prohibited status and many therapists are unsure of how they might practice in this area. This paper explicates such risks and describes ways in which therapists can mitigate them and strive to practice within legal and ethical boundaries. A harm reduction approach will be emphasized as a useful framework for conducting therapy around clients' use of psychedelics. It is argued that therapists can meet with clients before and after their own personal psychedelic experiences in order to help clients minimize risk and maximize benefit. Common clinical scenarios in this growing clinical area will also be discussed. Abstract Psychedelic-assisted therapy may represent an upcoming paradigm shift in the treatment of mental health problems as recent clinical trials have demonstrated strong evidence of their therapeutic benefits. While psychedelics are currently prohibited substances in most countries, the growing popularity of their therapeutic potential is leading many people to use psychedelics on their own rather than waiting for legal medical access. Therapists therefore have an ethical duty to meet this need by providing support for clients using psychedelics. However, incorporating psychedelics into traditional psychotherapy poses some risk given their prohibited status and many therapists are unsure of how they might practice in this area. This paper explicates such risks and describes ways in which therapists can mitigate them and strive to practice within legal and ethical boundaries. A harm reduction approach will be emphasized as a useful framework for conducting therapy around clients' use of psychedelics. It is argued that therapists can meet with clients before and after their own personal psychedelic experiences in order to help clients minimize risk and maximize benefit. Common clinical scenarios in this growing clinical area will also be discussed. Psychedelic-assisted therapy may represent an upcoming paradigm shift in the treatment of mental health problems as recent clinical trials have demonstrated strong evidence of their therapeutic benefits. While psychedelics are currently prohibited substances in most countries, the growing popularity of their therapeutic potential is leading many people to use psychedelics on their own rather than waiting for legal medical access. Therapists therefore have an ethical duty to meet this need by providing support for clients using psychedelics. However, incorporating psychedelics into traditional psychotherapy poses some risk given their prohibited status and many therapists are unsure of how they might practice in this area. This paper explicates such risks and describes ways in which therapists can mitigate them and strive to practice within legal and ethical boundaries. A harm reduction approach will be emphasized as a useful framework for conducting therapy around clients' use of psychedelics. It is argued that therapists can meet with clients before and after their own personal psychedelic experiences in order to help clients minimize risk and maximize benefit. Common clinical scenarios in this growing clinical area will also be discussed.Psychedelic-assisted therapy may represent an upcoming paradigm shift in the treatment of mental health problems as recent clinical trials have demonstrated strong evidence of their therapeutic benefits. While psychedelics are currently prohibited substances in most countries, the growing popularity of their therapeutic potential is leading many people to use psychedelics on their own rather than waiting for legal medical access. Therapists therefore have an ethical duty to meet this need by providing support for clients using psychedelics. However, incorporating psychedelics into traditional psychotherapy poses some risk given their prohibited status and many therapists are unsure of how they might practice in this area. This paper explicates such risks and describes ways in which therapists can mitigate them and strive to practice within legal and ethical boundaries. A harm reduction approach will be emphasized as a useful framework for conducting therapy around clients' use of psychedelics. It is argued that therapists can meet with clients before and after their own personal psychedelic experiences in order to help clients minimize risk and maximize benefit. Common clinical scenarios in this growing clinical area will also be discussed. Psychedelic-assisted therapy may represent an upcoming paradigm shift in the treatment of mental health problems as recent clinical trials have demonstrated strong evidence of their therapeutic benefits. While psychedelics are currently prohibited substances in most countries, the growing popularity of their therapeutic potential is leading many people to use psychedelics on their own rather than waiting for legal medical access. Therapists therefore have an ethical duty to meet this need by providing support for clients using psychedelics. However, incorporating psychedelics into traditional psychotherapy poses some risk given their prohibited status and many therapists are unsure of how they might practice in this area. This paper explicates such risks and describes ways in which therapists can mitigate them and strive to practice within legal and ethical boundaries. A harm reduction approach will be emphasized as a useful framework for conducting therapy around clients' use of psychedelics. It is argued that therapists can meet with clients before and after their own personal psychedelic experiences in order to help clients minimize risk and maximize benefit. Common clinical scenarios in this growing clinical area will also be discussed. Keywords: Psychedelics, Psychedelic-assisted therapy, Psychedelic integration, Harm reduction |
ArticleNumber | 40 |
Audience | Academic |
Author | Bathje, Geoff J. Pilecki, Brian Narloch, Vilmarie Fraguada Rhea, Joseph Luoma, Jason B. |
Author_xml | – sequence: 1 givenname: Brian orcidid: 0000-0002-6211-4586 surname: Pilecki fullname: Pilecki, Brian – sequence: 2 givenname: Jason B. surname: Luoma fullname: Luoma, Jason B. – sequence: 3 givenname: Geoff J. surname: Bathje fullname: Bathje, Geoff J. – sequence: 4 givenname: Joseph surname: Rhea fullname: Rhea, Joseph – sequence: 5 givenname: Vilmarie Fraguada surname: Narloch fullname: Narloch, Vilmarie Fraguada |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33827588$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kk1v1DAQhiNURD_gD3BAkbhwSfE4_rwgVVWBShVc4Gx5ncnGq6y92Eml_fd4d1voVgj54LH9zDu25z2vTkIMWFVvgVwCKPExA9WcNYRCQwhTuoEX1RkwKRvJQZ48iU-r85xXhBS-Va-q07ZVVHKlzqpvN9PgnR1rG7p6xGWJfM4z5tqHepO3bsAOR-_qwaZ1nbCb3eRj2OM-TLhMdr-eBkx2s31dveztmPHNw3xR_fx88-P6a3P3_cvt9dVd47hop0YwoFb2iJIpEE7wTlKnVStAO8tQIKCw4Cx2jiBq20KrpWYL6ogDZXl7Ud0edLtoV2aT_NqmrYnWm_1GTEtj0-TdiIYpxWGhlKSgGe9KyKlyUnNN6KK1omh9Omht5sW6VMQwJTseiR6fBD-YZbw3ilAlhS4CHx4EUvxVvm4ya58djqMNGOdsKAdCeekQK-j7Z-gqzimUr9pRTLWSCfhLlXag8aGPpa7biZorUc6lJKAKdfkPqowO194Vq_S-7B8lvHv60D8vfHRDAdQBcCnmnLA3zk_7_hZlPxogZmc8czCeKcYze-OZ3ZXps9RH9f8k_Qb1g9gl |
CitedBy_id | crossref_primary_10_3390_ejihpe14030038 crossref_primary_10_1177_02698811241249698 crossref_primary_10_1038_s41598_023_41145_x crossref_primary_10_1038_s41598_024_69688_7 crossref_primary_10_3390_psychoactives3030022 crossref_primary_10_1002_cpp_2880 crossref_primary_10_7759_cureus_45169 crossref_primary_10_1016_j_socscimed_2024_117134 crossref_primary_10_1080_02791072_2022_2108356 crossref_primary_10_3389_fpsyg_2023_1054692 crossref_primary_10_1016_j_drugpo_2024_104514 crossref_primary_10_1080_1177083X_2025_2467035 crossref_primary_10_1016_j_newideapsych_2022_100967 crossref_primary_10_1080_13803395_2024_2363343 crossref_primary_10_1093_nc_niad017 crossref_primary_10_1177_02698811241257839 crossref_primary_10_1177_07067437221111371 crossref_primary_10_1186_s12954_022_00662_0 crossref_primary_10_1615_IntJMedMushrooms_2024056373 crossref_primary_10_1016_j_drugpo_2021_103429 crossref_primary_10_1017_S1092852924002268 crossref_primary_10_1007_s13670_023_00383_7 crossref_primary_10_1080_02791072_2023_2276230 crossref_primary_10_1089_psymed_2024_0019 crossref_primary_10_1016_j_pnpbp_2024_111177 crossref_primary_10_1038_s41386_023_01710_4 crossref_primary_10_1176_appi_ps_20220525 crossref_primary_10_1558_ijsnr_20152 crossref_primary_10_3390_ph15050640 crossref_primary_10_1177_02698811231179801 crossref_primary_10_1089_psymed_2023_0004 crossref_primary_10_1186_s40337_024_01185_8 crossref_primary_10_1080_15401383_2023_2237868 crossref_primary_10_3389_fpsyg_2022_863247 crossref_primary_10_1038_s44220_024_00302_5 crossref_primary_10_1177_02698811231158245 crossref_primary_10_1111_anoc_12226 crossref_primary_10_1016_j_neuropharm_2024_110280 crossref_primary_10_1017_S1478951524001494 crossref_primary_10_1089_psymed_2024_0027 crossref_primary_10_59324_ejahss_2024_1_3__10 crossref_primary_10_61373_pp024r_0040 crossref_primary_10_1002_fhu2_70009 crossref_primary_10_1007_s00204_024_03765_8 crossref_primary_10_1002_fhu2_70004 crossref_primary_10_1007_s10615_025_00988_9 crossref_primary_10_1016_j_neuropharm_2022_109214 crossref_primary_10_3389_fpsyt_2021_737738 crossref_primary_10_3390_philosophies8050076 crossref_primary_10_1556_2054_2022_00211 crossref_primary_10_1016_j_jad_2023_03_083 crossref_primary_10_1007_s12152_023_09536_z crossref_primary_10_1093_tbm_ibae053 crossref_primary_10_1055_a_2282_4731 crossref_primary_10_1007_s12144_024_06272_2 crossref_primary_10_1080_14786419_2022_2103697 crossref_primary_10_1186_s40337_024_01125_6 crossref_primary_10_1089_psymed_2023_0074 crossref_primary_10_3389_fpsyg_2023_1119115 crossref_primary_10_1080_02791072_2022_2129885 crossref_primary_10_3174_ajnr_A8118 crossref_primary_10_1177_00221678221085800 crossref_primary_10_1556_2054_2022_00200 crossref_primary_10_1556_2054_2022_00207 crossref_primary_10_3390_cancers16091702 |
Cites_doi | 10.1177/0022167816670996 10.1016/S0140-6736(10)61462-6 10.1046/j.1360-0443.2001.96811397.x 10.1002/jclp.20669 10.1177/0269881108093587 10.1080/10508422.2013.860030 10.1016/j.jcbs.2019.12.004 10.1093/jtm/tax068 10.1177/009318531103900204 10.1556/2054.2019.016 10.2190/W6L6-G171-M4FT-TWAP 10.15288/jsad.2015.76.749 10.1556/2054.2019.015 10.3389/fphar.2018.00733 10.1186/1471-2458-14-297 10.1016/S0140-6736(02)08701-9 10.1007/978-1-4899-1934-2_24 10.1556/2054.2019.003 10.1186/2211-1522-2-1 10.1556/2054.2019.031 10.1186/s12888-018-1824-6 10.1177/0269881118806297 10.1177/0269881112439253 10.1016/j.drugpo.2014.11.007 10.1080/00275514.1971.12019194 10.1177/0269881116675513 10.1016/j.pharmthera.2018.11.010 10.1038/nrn3530 10.1080/16066359.2016.1242722 10.7326/0003-4819-148-10-200805200-00215 10.1093/hsw/28.2.117 10.1016/j.drugpo.2018.11.001 10.1007/s00213-018-5010-9 10.1080/02791072.1998.10399712 10.1080/02791072.2014.973125 10.12688/f1000research.2-98.v1 10.1556/2054.2020.00124 10.1007/s00213-017-4771-x 10.1126/science.163.3864.245 10.1124/pr.115.011478 10.4135/9781452220680.n1 10.3310/hta11090 10.1177/0022167816673493 10.3109/00952990.2016.1170135 10.1080/02791072.2020.1769878 10.1071/NB10007 10.1007/BF02862854 10.1556/2054.2018.001 10.1080/1751696X.2014.993244 |
ContentType | Journal Article |
Copyright | COPYRIGHT 2021 BioMed Central Ltd. 2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. The Author(s) 2021 |
Copyright_xml | – notice: COPYRIGHT 2021 BioMed Central Ltd. – notice: 2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: The Author(s) 2021 |
DBID | AAYXX CITATION NPM 3V. 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AEUYN AFKRA ATCPS AZQEC BENPR BHPHI CCPQU DWQXO FYUFA GHDGH GNUQQ HCIFZ K9. M0S M1P PATMY PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS PYCSY 7X8 5PM DOA |
DOI | 10.1186/s12954-021-00489-1 |
DatabaseName | CrossRef PubMed ProQuest Central (Corporate) Health & Medical Collection (ProQuest) ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central ProQuest One Sustainability ProQuest Central UK/Ireland Agricultural & Environmental Science Collection ProQuest Central Essentials ProQuest Central Database Suite (ProQuest) Natural Science Collection ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student SciTech Collection (ProQuest) ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Medical Database Environmental Science Database ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China Environmental Science Collection MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ: Directory of Open Access Journal (DOAJ) |
DatabaseTitle | CrossRef PubMed Publicly Available Content Database ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central ProQuest One Sustainability ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Health & Medical Research Collection Agricultural & Environmental Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) Environmental Science Collection ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition Environmental Science Database ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | Publicly Available Content Database CrossRef MEDLINE - Academic PubMed |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journal Collection url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Social Welfare & Social Work |
EISSN | 1477-7517 |
EndPage | 14 |
ExternalDocumentID | oai_doaj_org_article_48851b88721945d1b8528c795902b3a6 PMC8028769 A661377018 33827588 10_1186_s12954_021_00489_1 |
Genre | Letter Correspondence |
GeographicLocations | United States United States--US |
GeographicLocations_xml | – name: United States – name: United States--US |
GrantInformation_xml | – fundername: ; |
GroupedDBID | --- 0R~ 29I 2WC 2XV 53G 5GY 5VS 7X7 7XC 88E 8FE 8FH 8FI 8FJ AAFWJ AAJSJ AASML AAYXX ABDBF ABIVO ABUWG ACGFO ACGFS ACHQT ACIHN ACUHS ADBBV ADRAZ ADUKV AEAQA AEUYN AFKRA AFPKN AFRAH AHBYD AHMBA AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS ATCPS BAPOH BAWUL BCNDV BENPR BFQNJ BHPHI BMC BPHCQ BVXVI C6C CCPQU CITATION CS3 DIK DU5 E3Z EBD EBLON EBS EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 HCIFZ HMCUK HYE IAO IHR INH INR IPY ITC KQ8 M1P M48 M~E O5R O5S OK1 OVT P2P PATMY PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO PYCSY RBZ RNS ROL RPM RSV SMD SOJ SV3 TR2 TUS UKHRP WOQ WOW XSB ~8M NPM PMFND 3V. 7XB 8FK AZQEC DWQXO GNUQQ K9. PJZUB PKEHL PPXIY PQEST PQUKI PRINS 7X8 5PM PUEGO |
ID | FETCH-LOGICAL-c563t-6412a7fee74816c65d72c983619ca4e6e1e6a1caedc0ee9a3139794b2c0c18a53 |
IEDL.DBID | 7X7 |
ISSN | 1477-7517 |
IngestDate | Wed Aug 27 00:54:58 EDT 2025 Thu Aug 21 18:36:51 EDT 2025 Fri Jul 11 04:14:34 EDT 2025 Fri Jul 25 22:27:33 EDT 2025 Tue Jun 17 21:08:15 EDT 2025 Tue Jun 10 20:28:01 EDT 2025 Thu Apr 03 07:03:21 EDT 2025 Thu Apr 24 23:07:17 EDT 2025 Tue Jul 01 00:46:58 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Keywords | Harm reduction Psychedelic integration Psychedelic-assisted therapy Psychedelics |
Language | English |
License | Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c563t-6412a7fee74816c65d72c983619ca4e6e1e6a1caedc0ee9a3139794b2c0c18a53 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Correspondence-1 |
ORCID | 0000-0002-6211-4586 |
OpenAccessLink | https://www.proquest.com/docview/2514837461?pq-origsite=%requestingapplication% |
PMID | 33827588 |
PQID | 2514837461 |
PQPubID | 105462 |
PageCount | 14 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_48851b88721945d1b8528c795902b3a6 pubmedcentral_primary_oai_pubmedcentral_nih_gov_8028769 proquest_miscellaneous_2510250484 proquest_journals_2514837461 gale_infotracmisc_A661377018 gale_infotracacademiconefile_A661377018 pubmed_primary_33827588 crossref_citationtrail_10_1186_s12954_021_00489_1 crossref_primary_10_1186_s12954_021_00489_1 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2021-04-07 |
PublicationDateYYYYMMDD | 2021-04-07 |
PublicationDate_xml | – month: 04 year: 2021 text: 2021-04-07 day: 07 |
PublicationDecade | 2020 |
PublicationPlace | England |
PublicationPlace_xml | – name: England – name: London |
PublicationTitle | Harm reduction journal |
PublicationTitleAlternate | Harm Reduct J |
PublicationYear | 2021 |
Publisher | BioMed Central Ltd BioMed Central BMC |
Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central – name: BMC |
References | 489_CR66 DJ Nutt (489_CR49) 2010; 376 JH Tanne (489_CR14) 2014; 328 AT Shulgin (489_CR15) 1978 ECHM Haijen (489_CR27) 2018; 2018 A Tatarsky (489_CR39) 2002 489_CR60 RR Griffiths (489_CR20) 2016; 30 DE Logan (489_CR41) 2010; 66 JR George (489_CR62) 2020; 4 489_CR64 MN Steers (489_CR56) 2015; 76 M Pollan (489_CR1) 2018 P Denning (489_CR47) 2004 A Wodak (489_CR42) 2010; 21 GT Flaherty (489_CR5) 2017; 24 E Fotiou (489_CR65) 2020; 4 RJ Vallerand (489_CR53) 2012; 2 Z Postranecka (489_CR13) 2019; 3 DP Wilson (489_CR43) 2015; 26 RE Schultes (489_CR7) 1969; 163 MW Johnson (489_CR25) 2008; 22 JC Callaway (489_CR50) 1998; 30 ER Weitzman (489_CR45) 2004; 34 489_CR17 MP Bogenschutz (489_CR21) 2017; 57 MW Johnson (489_CR3) 2019; 197 AK Davis (489_CR55) 2017; 25 JB Luoma (489_CR2) 2020; 52 J Brocato (489_CR36) 2003; 28 A Hofmann (489_CR11) 2013 MW Johnson (489_CR22) 2016; 43 AM Haeny (489_CR58) 2014; 24 TS Krebs (489_CR23) 2012; 26 AK Davis (489_CR54) 2015; 47 AL Danforth (489_CR24) 2018; 235 P Denning (489_CR37) 2011 E Ekman Schenberg (489_CR69) 2018; 9 TG Gutheil (489_CR59) 2011; 39 B Lowy (489_CR8) 1971; 63 MT Williams (489_CR68) 2020; 4 DE Nichols (489_CR57) 2016; 68 K Weingardt (489_CR40) 1998 M Doe-Simkins (489_CR46) 2014; 14 FC Measham (489_CR52) 2019; 67 E Guerra-Doce (489_CR6) 2015; 8 AR Winstock (489_CR51) 2001; 96 WA Richards (489_CR28) 2017; 57 G Ona (489_CR32) 2018; 2 EE Schenberg (489_CR26) 2018; 9 N Heather (489_CR35) 1993 D Peluso (489_CR61) 2020; 4 H Liu (489_CR48) 2008; 148 SC Carlin (489_CR70) 2019; 29 TS Krebs (489_CR4) 2013; 2 L Grinspoon (489_CR12) 1979 489_CR33 489_CR34 489_CR38 489_CR30 M Connock (489_CR44) 2007; 11 JG Bruhn (489_CR9) 2002; 359 TI Michaels (489_CR63) 2018; 18 489_CR29 DJ Nutt (489_CR16) 2013; 14 GM Ot'alora (489_CR18) 2018; 32 R Watts (489_CR31) 2020; 15 MT Williams (489_CR67) 2020; 4 JG Bruhn (489_CR10) 1973; 28 RL Carhart-Harris (489_CR19) 2018; 235 |
References_xml | – ident: 489_CR33 – volume: 57 start-page: 323 year: 2017 ident: 489_CR28 publication-title: J Humanist Psychol doi: 10.1177/0022167816670996 – volume: 376 start-page: 1558 year: 2010 ident: 489_CR49 publication-title: Lancet doi: 10.1016/S0140-6736(10)61462-6 – volume: 96 start-page: 1139 year: 2001 ident: 489_CR51 publication-title: Addiction doi: 10.1046/j.1360-0443.2001.96811397.x – ident: 489_CR66 – volume: 66 start-page: 201 year: 2010 ident: 489_CR41 publication-title: J Clin Psychol doi: 10.1002/jclp.20669 – volume-title: How to change your mind: what the new science of psychedelics teaches us about consciousness, dying, addiction, depression, and transcendence year: 2018 ident: 489_CR1 – volume: 22 start-page: 603 issue: 6 year: 2008 ident: 489_CR25 publication-title: J Psychopharmacol doi: 10.1177/0269881108093587 – volume: 24 start-page: 265 year: 2014 ident: 489_CR58 publication-title: Ethics Behav doi: 10.1080/10508422.2013.860030 – volume: 15 start-page: 92 year: 2020 ident: 489_CR31 publication-title: J Context Behav Sci doi: 10.1016/j.jcbs.2019.12.004 – volume: 24 start-page: 1 issue: 6 year: 2017 ident: 489_CR5 publication-title: J Travel Med doi: 10.1093/jtm/tax068 – volume: 39 start-page: 237 year: 2011 ident: 489_CR59 publication-title: J Psychiatry Law doi: 10.1177/009318531103900204 – volume: 4 start-page: 40 year: 2020 ident: 489_CR67 publication-title: J Psychedelic Stud doi: 10.1556/2054.2019.016 – volume: 34 start-page: 247 year: 2004 ident: 489_CR45 publication-title: J Drug Educ doi: 10.2190/W6L6-G171-M4FT-TWAP – volume: 76 start-page: 749 year: 2015 ident: 489_CR56 publication-title: J Stud Alcohol Drugs doi: 10.15288/jsad.2015.76.749 – volume: 4 start-page: 4 year: 2020 ident: 489_CR62 publication-title: J Psychedelic Stud doi: 10.1556/2054.2019.015 – volume: 9 start-page: 733 year: 2018 ident: 489_CR69 publication-title: Front Pharmacol doi: 10.3389/fphar.2018.00733 – volume: 14 start-page: 297 issue: 1 year: 2014 ident: 489_CR46 publication-title: BMC Public Health doi: 10.1186/1471-2458-14-297 – volume: 359 start-page: 1866 issue: 9320 year: 2002 ident: 489_CR9 publication-title: Lancet doi: 10.1016/S0140-6736(02)08701-9 – volume: 29 start-page: 10 issue: 1 year: 2019 ident: 489_CR70 publication-title: MAPS Bull Spring – start-page: 337 volume-title: Treating addictive behaviors year: 1998 ident: 489_CR40 doi: 10.1007/978-1-4899-1934-2_24 – volume: 3 start-page: 19 issue: 1 year: 2019 ident: 489_CR13 publication-title: J Psychedelic Stud doi: 10.1556/2054.2019.003 – volume: 2 start-page: 1 year: 2012 ident: 489_CR53 publication-title: Psychol Well-Being doi: 10.1186/2211-1522-2-1 – volume: 4 start-page: 16 year: 2020 ident: 489_CR65 publication-title: J Psychedelic Stud doi: 10.1556/2054.2019.031 – volume: 18 start-page: 1 year: 2018 ident: 489_CR63 publication-title: BMC Psychiatry doi: 10.1186/s12888-018-1824-6 – volume-title: Psychedelic drugs reconsidered year: 1979 ident: 489_CR12 – volume: 32 start-page: 1295 issue: 12 year: 2018 ident: 489_CR18 publication-title: J Psychopharmacol doi: 10.1177/0269881118806297 – volume: 26 start-page: 994 issue: 7 year: 2012 ident: 489_CR23 publication-title: J Psychopharmacol doi: 10.1177/0269881112439253 – volume: 26 start-page: S5 year: 2015 ident: 489_CR43 publication-title: Int J Drug Policy doi: 10.1016/j.drugpo.2014.11.007 – volume: 63 start-page: 983 year: 1971 ident: 489_CR8 publication-title: Mycologia doi: 10.1080/00275514.1971.12019194 – ident: 489_CR17 – volume: 30 start-page: 1181 issue: 12 year: 2016 ident: 489_CR20 publication-title: J Psychopharmacol doi: 10.1177/0269881116675513 – ident: 489_CR30 – volume: 197 start-page: 83 year: 2019 ident: 489_CR3 publication-title: Pharmacol Ther doi: 10.1016/j.pharmthera.2018.11.010 – ident: 489_CR38 – volume: 14 start-page: 577 year: 2013 ident: 489_CR16 publication-title: Nat Rev Neurosci doi: 10.1038/nrn3530 – ident: 489_CR60 – volume-title: Practicing harm reduction psychotherapy: an alternative approach to addictions year: 2004 ident: 489_CR47 – volume: 25 start-page: 188 issue: 3 year: 2017 ident: 489_CR55 publication-title: Addict Res Theory doi: 10.1080/16066359.2016.1242722 – volume-title: Psychoactive drugs and harm reduction: from faith to science year: 1993 ident: 489_CR35 – volume: 148 start-page: 747 issue: 10 year: 2008 ident: 489_CR48 publication-title: Ann Intern Med doi: 10.7326/0003-4819-148-10-200805200-00215 – ident: 489_CR29 – volume: 28 start-page: 117 year: 2003 ident: 489_CR36 publication-title: Health Soc Work doi: 10.1093/hsw/28.2.117 – volume: 67 start-page: 102 year: 2019 ident: 489_CR52 publication-title: Int J Drug Policy doi: 10.1016/j.drugpo.2018.11.001 – volume: 235 start-page: 3137 issue: 11 year: 2018 ident: 489_CR24 publication-title: Psychopharmacology doi: 10.1007/s00213-018-5010-9 – ident: 489_CR64 – volume: 328 start-page: 713 issue: 7441 year: 2014 ident: 489_CR14 publication-title: BMJ – volume-title: Practicing harm reduction psychotherapy: an alternative approach to addictions year: 2011 ident: 489_CR37 – volume: 30 start-page: 367 year: 1998 ident: 489_CR50 publication-title: J Psychoact Drugs doi: 10.1080/02791072.1998.10399712 – volume: 47 start-page: 24 year: 2015 ident: 489_CR54 publication-title: J Psychoact Drugs doi: 10.1080/02791072.2014.973125 – volume: 2 start-page: 98 year: 2013 ident: 489_CR4 publication-title: F1000Research doi: 10.12688/f1000research.2-98.v1 – volume: 4 start-page: 24 year: 2020 ident: 489_CR61 publication-title: J Psychedelic Stud doi: 10.1556/2054.2020.00124 – volume: 235 start-page: 399 issue: 2 year: 2018 ident: 489_CR19 publication-title: Psychopharmacology doi: 10.1007/s00213-017-4771-x – volume: 163 start-page: 245 issue: 3864 year: 1969 ident: 489_CR7 publication-title: Science doi: 10.1126/science.163.3864.245 – volume: 4 start-page: 1 issue: 245 year: 2020 ident: 489_CR68 publication-title: J Psychedelic Stud – volume-title: The psychopharmacology of hallucinogens year: 1978 ident: 489_CR15 – volume: 68 start-page: 264 year: 2016 ident: 489_CR57 publication-title: Pharmacol Rev doi: 10.1124/pr.115.011478 – volume-title: LSD: my problem child year: 2013 ident: 489_CR11 – volume: 9 start-page: 1 year: 2018 ident: 489_CR26 publication-title: Front Pharmacol doi: 10.3389/fphar.2018.00733 – volume: 2018 start-page: 1 issue: 9 year: 2018 ident: 489_CR27 publication-title: Front Pharmacol – ident: 489_CR34 doi: 10.4135/9781452220680.n1 – volume: 11 start-page: 1 year: 2007 ident: 489_CR44 publication-title: Health Technol Assess doi: 10.3310/hta11090 – volume: 57 start-page: 389 year: 2017 ident: 489_CR21 publication-title: J Humanist Psychol doi: 10.1177/0022167816673493 – volume: 43 start-page: 55 issue: 1 year: 2016 ident: 489_CR22 publication-title: J Drug Alcohol Abuse doi: 10.3109/00952990.2016.1170135 – volume-title: Harm reduction psychotherapy year: 2002 ident: 489_CR39 – volume: 52 start-page: 289 issue: 4 year: 2020 ident: 489_CR2 publication-title: J Psychoact Drugs doi: 10.1080/02791072.2020.1769878 – volume: 21 start-page: 69 year: 2010 ident: 489_CR42 publication-title: NSW Public Health Bulletin doi: 10.1071/NB10007 – volume: 28 start-page: 353 year: 1973 ident: 489_CR10 publication-title: Econ Bot doi: 10.1007/BF02862854 – volume: 2 start-page: 53 year: 2018 ident: 489_CR32 publication-title: J Psychedelic Stud doi: 10.1556/2054.2018.001 – volume: 8 start-page: 91 issue: 1 year: 2015 ident: 489_CR6 publication-title: Time Mind J Archaeol Conscious Cult doi: 10.1080/1751696X.2014.993244 |
SSID | ssj0029538 |
Score | 2.5055578 |
Snippet | Psychedelic-assisted therapy may represent an upcoming paradigm shift in the treatment of mental health problems as recent clinical trials have demonstrated... Abstract Psychedelic-assisted therapy may represent an upcoming paradigm shift in the treatment of mental health problems as recent clinical trials have... |
SourceID | doaj pubmedcentral proquest gale pubmed crossref |
SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
StartPage | 40 |
SubjectTerms | Clients Clinical trials Ecstasy Ethical aspects Ethics Hallucinogenic drugs Harm reduction Health problems Laws, regulations and rules Legal issues LSD Lysergic acid diethylamide Marginalized groups Medical ethics Mental disorders Mental health Mental health care Methods Opinion Post traumatic stress disorder Psychedelic drugs Psychedelic integration Psychedelic-assisted therapy Psychedelics Psychotherapy Reduction Risk reduction Therapists Therapy |
SummonAdditionalLinks | – databaseName: DOAJ: Directory of Open Access Journal (DOAJ) dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQT70gaHkEtshICA4oahw7fhwLoqqQ6ImK3izHnogVqyza3R767zvjJKuNkODCLY4nie2Zib-Rx58Ze1dZcLIJGpGbSqUKqSoRHMVS1ZA6rWxUgVZ0v13rqxv19ba5PTjqi3LCBnrgYeDO0cAa0aIroGupJuFlU9tIJ2RXdStDJtvGOW8KpsZQy6EfT1tkrD7fClrOKikdgUzWlWI2DWW2_j__yQeT0jxh8mAGunzCHo_QkV8MTX7KHkF_whbD_lr-A1Zd2AB_z6cb682vU3ad89mxGPrEV4Cf5nmkt3zZ85zpDAlWy8iJwZpviMeVNJXFJyYJKg_btO6fsZvLL98_X5XjEQplbLTclVqJOpgOwCgrdNRNMnV0VmLYFIMCDQJ0EDFg1yoAFyQBQqfaOlZR2NDI5-yoX_fwkvGUDCCY6qSjlTnoQuuia1JrwaQg21QwMY2ojyO_OB1zsfI5zrDaD1rwqAWfteBFwT7un_k9sGv8VfoTKWovSczY-Qbaix_txf_LXgr2gdTsyX-xeTGM2xCwk8SE5S8QsEhjKmELtphJot_FefVkKH70-61HtEgU_UpjY9_uq-lJymXrYX2XZTJxnFUFezHY1b5LUtoaIzh8uZlZ3KzP85p--TOzgltEika7V_9jkF6z4zo7C_qMWbCj3eYOzhB87do32c8eAPXmKBA priority: 102 providerName: Directory of Open Access Journals – databaseName: Scholars Portal Journals: Open Access dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3Ni9UwEA_LevEiflt9SgTRg1TbJk3Sg8gqLouwe_Lh3kKaTPVh6dO-t-D-986kH2xx2VvTTNokM5PMkMlvGHuVGahE6RRabjKk0oUsRePIp7KA0ChpvHR0ont6pk7W8ut5eX7ApnRH4wTurnXtKJ_Uum_f_f1z-REV_kNUeKPe73I6rEop2IAEskrRG7qFO5MmRT2V86kCUgkzXZy5tt1ic4oY_v-v1Fe2qmUY5ZV96fguuzMalPxokIB77AC6-2w13Lrl36FtXA_8NZ9ebPtfD9hZjHLHousCbwF_zeP87_im4zH-GQK0G88J15r3hO5K_IvkE74ElYfLW5cP2fr4y7fPJ-mYWCH1pRL7VMm8cLoB0NLkyqsy6MJXRqAz5Z0EBTkol3uHQ8sAKifITKxkXfjM58aV4hE77LYdPGE8BA1oYjWiovM6aFxd-aoMtQEdnKhDwvJpRq0fUccp-UVro_dhlB24YJELNnLB5gl7O7f5PWBu3Ej9iRg1UxJednyx7X_YUf0sLlNlXuOCigu0LAM-loXxlGc9K2rhVMLeEJstyRl2z7vxcgIOkvCx7BGaMULrLDcJWy0oURv9snoSFDsJs0UbkoD7pcLOvpyrqSVFuHWwvYg0EU7OyIQ9HuRqHpIQpkC_Dj-uFxK3GPOyptv8jFjhBu1HraqnN3frGbtdRDVAbdArdrjvL-A5Glv7-kXUoH-24CS8 priority: 102 providerName: Scholars Portal |
Title | Ethical and legal issues in psychedelic harm reduction and integration therapy |
URI | https://www.ncbi.nlm.nih.gov/pubmed/33827588 https://www.proquest.com/docview/2514837461 https://www.proquest.com/docview/2510250484 https://pubmed.ncbi.nlm.nih.gov/PMC8028769 https://doaj.org/article/48851b88721945d1b8528c795902b3a6 |
Volume | 18 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELagvXBBvAldVkZCcEBR49ixnRPaolbVSl0hoGJvlmN7YcUqKdntof-eGSfZNkLqJS9PHs48PLbH3xDyPtOh5IWV4LkJnwrrsxScI5eKPPiVFNoJizO6Fwt5finmy2LZD7ht-7DKwSZGQ-0bh2Pkx9AOI_i5kOzz1d8Us0bh7GqfQuMhOUToMgzpUsvbDlcJ2jwslNHyeMtwUivFoAQU3DJlo8YoYvb_b5nvNE3jsMk77dDZE_K4dyDprOP4U_Ig1M_IpFtlS3-Gzcq2gX6gw4Wm_fOcLGJUO5za2tNNgFfT-L-3dF3TGO8cfNisHUUca9oimivyK5IPeBJ43i3WunlBLs9Of3w5T_tECqkrJN-lUrDcqlUISmgmnSy8yl2pOXSenBVBBhakZc5C1bIQSsvRLSxFlbvMMW0L_pIc1E0dXhPqvQrgUq14ifNzYWWr0pWFr3RQ3vLKJ4QNf9S4HmUck11sTOxtaGk6LhjggolcMCwhn_b3XHUYG_dSnyCj9pSIjx0vNO0v06ubAbNUsAoMKBhkUXg4LHLtMK96llfcyoR8RDYb1GL4PGf7xQhQScTDMjNwW7hSGdMJmYwoQfvcuHgQFNNr_9bcympC3u2L8U6MaKtDcx1pInycFgl51cnVvkqc6xz6cfBwNZK4UZ3HJfX6d8QG1-AvKlm-uf-zjsijPKoBaIOakINdex3egnO1q6ZRg6bkcDabf5_D_uR08fXbNA5VwPZC6H-K2yaI |
linkProvider | ProQuest |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3Nb9MwFLem7gAXxDeBAkbi44CixYnjOAeENtjUsa1CaBO7Gcd-hYoqHW0ntH-Kv5H3nKQsQtpttyR-SeO87_r59xh7mWgos9wqjNykj6X1SYzBkYtlCn6ipHbS0oru0ViNTuSn0_x0g_3p9sJQWWVnE4Oh9nNH_5FvoR8m8HOpxPuzXzF1jaLV1a6FRiMWB3DxG1O25bv9j8jfV2m6t3v8YRS3XQVil6tsFSspUltMAAqphXIq90XqSp1hJuGsBAUClBXOgncJQGkzipFKWaUucUJb6hKBJn9TZpjKDNjmzu7485d1ilei_ei25mi1tRS0jBZTGQSpShmLnvsLXQL-9wWXnGG_UPOS59u7zW61ISvfbmTsDtuA-i4bNvt6-VeYTewC-GveXZgvft5j41BHj6e29nwG-NM8cHjJpzUPFdbgYTZ1nJCz-YLwY0lCAnmHYEHnzfawi_vs5Fo-8gM2qOc1PGLc-wIwiJtkJa0IwsRWpStzX2kovM0qHzHRfVHjWlxzaq8xMyG_0co0XDDIBRO4YETE3q7vOWtQPa6k3iFGrSkJkTtcmC--m1bBDRrCXFRostEFyNzjYZ5qR53ck7TKrIrYG2KzIbuBr-dsu_0BJ0kIXGYbA6WsKBKhIzbsUaK-u_5wJyimtTdL8087IvZiPUx3Ug1dDfPzQBMA67SM2MNGrtZTyjKdYuaIDy96Etebc3-knv4IaOQaI9RClY-vfq3n7Mbo-OjQHO6PD56wm2lQCdSMYsgGq8U5PMXQblU9a_WJs2_XrcJ_AX_eYAI |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Ethical+and+legal+issues+in+psychedelic+harm+reduction+and+integration+therapy&rft.jtitle=Harm+reduction+journal&rft.au=Pilecki%2C+Brian&rft.au=Luoma%2C+Jason+B&rft.au=Bathje%2C+Geoff+J&rft.au=Rhea%2C+Joseph&rft.date=2021-04-07&rft.pub=BioMed+Central&rft.eissn=1477-7517&rft.volume=18&rft.spage=1&rft_id=info:doi/10.1186%2Fs12954-021-00489-1 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1477-7517&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1477-7517&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1477-7517&client=summon |